Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Prediction of Drug Approval After Phase I Clinical Trials in Oncology: RESOLVED2.

Beinse G, Tellier V, Charvet V, Deutsch E, Borget I, Massard C, Hollebecque A, Verlingue L.

JCO Clin Cancer Inform. 2019 Sep;3:1-10. doi: 10.1200/CCI.19.00023.

2.

Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade.

Jacquelot N, Yamazaki T, Roberti MP, Duong CPM, Andrews MC, Verlingue L, Ferrere G, Becharef S, Vétizou M, Daillère R, Messaoudene M, Enot DP, Stoll G, Ugel S, Marigo I, Foong Ngiow S, Marabelle A, Prevost-Blondel A, Gaudreau PO, Gopalakrishnan V, Eggermont AM, Opolon P, Klein C, Madonna G, Ascierto PA, Sucker A, Schadendorf D, Smyth MJ, Soria JC, Kroemer G, Bronte V, Wargo J, Zitvogel L.

Cell Res. 2019 Oct;29(10):846-861. doi: 10.1038/s41422-019-0224-x. Epub 2019 Sep 3.

PMID:
31481761
3.

A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.

Sun R, Limkin EJ, Vakalopoulou M, Dercle L, Champiat S, Han SR, Verlingue L, Brandao D, Lancia A, Ammari S, Hollebecque A, Scoazec JY, Marabelle A, Massard C, Soria JC, Robert C, Paragios N, Deutsch E, Ferté C.

Lancet Oncol. 2018 Sep;19(9):1180-1191. doi: 10.1016/S1470-2045(18)30413-3. Epub 2018 Aug 14.

PMID:
30120041
4.

Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers.

Cabel L, Fuerea A, Lacroix L, Baldini C, Martin P, Hollebecque A, Postel-Vinay S, Varga A, Balheda R, Gazzah A, Michot JM, Marabelle A, Rouleau E, Solary E, De Baere T, Angevin E, Armand JP, Michiels S, Scoazec JY, Ammari S, André F, Soria JC, Massard C, Verlingue L.

Oncotarget. 2018 Jan 12;9(11):9741-9750. doi: 10.18632/oncotarget.24188. eCollection 2018 Feb 9.

5.

Corrigendum to "Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial" [Eur J Cancer 87 (2017) 122-130].

Verlingue L, Malka D, Allorant A, Massard C, Ferté C, Lacroix L, Rouleau E, Auger N, Ngo M, Nicotra C, De Baere T, Tselikas L, Ba B, Michiels S, Scoazec JY, Boige V, Ducreux M, Soria JC, Hollebecque A.

Eur J Cancer. 2018 Apr;93:156-157. doi: 10.1016/j.ejca.2018.01.077. Epub 2018 Feb 14. No abstract available.

PMID:
29454743
6.

Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door.

Verlingue L, Hollebecque A, Lacroix L, Postel-Vinay S, Varga A, El Dakdouki Y, Baldini C, Balheda R, Gazzah A, Michot JM, Marabelle A, Mir O, Arnedos M, Rouleau E, Solary E, De Baere T, Angevin E, Armand JP, Michiels S, André F, Deutsch E, Scoazec JY, Soria JC, Massard C.

Eur J Cancer. 2018 Mar;92:1-10. doi: 10.1016/j.ejca.2017.12.020. Epub 2018 Feb 3.

PMID:
29413684
7.

Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase-mutated intrahepatic cholangiocarcinomas.

Delahousse J, Verlingue L, Broutin S, Legoupil C, Touat M, Doucet L, Ammari S, Lacroix L, Ducreux M, Scoazec JY, Malka D, Paci A, Hollebecque A.

Eur J Cancer. 2018 Feb;90:83-91. doi: 10.1016/j.ejca.2017.11.024. Epub 2018 Jan 4.

PMID:
29274619
8.

Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial.

Verlingue L, Malka D, Allorant A, Massard C, Ferté C, Lacroix L, Rouleau E, Auger N, Ngo M, Nicotra C, De Baere T, Tselikas L, Ba B, Michiels S, Scoazec JY, Boige V, Ducreux M, Soria JC, Hollebecque A.

Eur J Cancer. 2017 Dec;87:122-130. doi: 10.1016/j.ejca.2017.10.013. Epub 2017 Nov 14. Erratum in: Eur J Cancer. 2018 Feb 14;:.

PMID:
29145038
9.

Angiogenesis inhibition in the second-line treatment of metastatic colorectal cancer: A systematic review and pooled analysis.

Chebib R, Verlingue L, Cozic N, Faron M, Burtin P, Boige V, Hollebecque A, Malka D.

Semin Oncol. 2017 Apr;44(2):114-128. doi: 10.1053/j.seminoncol.2017.07.004. Epub 2017 Aug 2. Review.

PMID:
28923209
10.

Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine.

Nebot-Bral L, Brandao D, Verlingue L, Rouleau E, Caron O, Despras E, El-Dakdouki Y, Champiat S, Aoufouchi S, Leary A, Marabelle A, Malka D, Chaput N, Kannouche PL.

Eur J Cancer. 2017 Oct;84:290-303. doi: 10.1016/j.ejca.2017.07.026. Epub 2017 Aug 29. Review.

PMID:
28846956
11.

[The breakthrough of personalized medicine, new hopes and new challenges].

Flippot R, Massard C, Auclin E, Azria D, Bourien H, Rochigneux P, Schernberg A, Verlingue L, Zafrani L, Vignot S.

Bull Cancer. 2017 Sep;104(9):735-743. doi: 10.1016/j.bulcan.2017.07.003. Epub 2017 Aug 12. Review. French.

PMID:
28807365
12.

Matching genomic molecular aberrations with molecular targeted agents: Are biliary tract cancers an ideal playground?

Verlingue L, Hollebecque A, Boige V, Ducreux M, Malka D, Ferté C.

Eur J Cancer. 2017 Aug;81:161-173. doi: 10.1016/j.ejca.2017.05.006. Epub 2017 Jun 17. Review.

PMID:
28628842
13.

High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial.

Massard C, Michiels S, Ferté C, Le Deley MC, Lacroix L, Hollebecque A, Verlingue L, Ileana E, Rosellini S, Ammari S, Ngo-Camus M, Bahleda R, Gazzah A, Varga A, Postel-Vinay S, Loriot Y, Even C, Breuskin I, Auger N, Job B, De Baere T, Deschamps F, Vielh P, Scoazec JY, Lazar V, Richon C, Ribrag V, Deutsch E, Angevin E, Vassal G, Eggermont A, André F, Soria JC.

Cancer Discov. 2017 Jun;7(6):586-595. doi: 10.1158/2159-8290.CD-16-1396. Epub 2017 Apr 1.

14.

A comprehensive approach to the molecular determinants of lifespan using a Boolean model of geroconversion.

Verlingue L, Dugourd A, Stoll G, Barillot E, Calzone L, Londoño-Vallejo A.

Aging Cell. 2016 Dec;15(6):1018-1026. doi: 10.1111/acel.12504. Epub 2016 Sep 9.

15.

[ESMO ECCO 2015: The highlights of immunotherapy and targeted therapies].

Bonnet C, Beinse G, Cabel L, Cochereau D, Lavaud P, Rochefort P, Tabouret E, Turpin A, Verlingue L, Vicier C, Massard C.

Bull Cancer. 2016 Jun;103(6):594-603. doi: 10.1016/j.bulcan.2016.04.001. Epub 2016 May 24. French.

PMID:
27229364
16.

The spectrum of clinical trials aiming at personalizing medicine.

Le Tourneau C, Kamal M, Alt M, Verlingue L, Servois V, Sablin MP, Servant N, Paoletti X.

Chin Clin Oncol. 2014 Jun;3(2):13. doi: 10.3978/j.issn.2304-3865.2014.05.02.

17.

Should we resist to including tumour growth patterns in Response Evaluation Criteria in Solid Tumours evaluation? (Response to Litière et al.).

Verlingue L, Koscielny S, Ferté C.

Eur J Cancer. 2014 Nov;50(16):2887-8. doi: 10.1016/j.ejca.2014.07.026. Epub 2014 Sep 15. No abstract available.

PMID:
25218336
18.

Challenges for the implementation of high-throughput testing and liquid biopsies in personalized medicine cancer trials.

Verlingue L, Alt M, Kamal M, Sablin MP, Zoubir M, Bousetta N, Pierga JY, Servant N, Paoletti X, Le Tourneau C.

Per Med. 2014 Jul;11(5):545-558. doi: 10.2217/pme.14.30.

PMID:
29758779
19.

[10-year outcome of aortocoronary bypass. Apropos of a consecutive series of 114 patients].

Adams C, Verlingue L, Le Feuvre C, Metzger JP, Heulin A, Vacheron A.

Ann Med Interne (Paris). 1989;140(1):5-8. Review. French.

PMID:
2660653

Supplemental Content

Loading ...
Support Center